CA2434691A1 - Use of propentofylline to control intraocular pressure - Google Patents
Use of propentofylline to control intraocular pressure Download PDFInfo
- Publication number
- CA2434691A1 CA2434691A1 CA002434691A CA2434691A CA2434691A1 CA 2434691 A1 CA2434691 A1 CA 2434691A1 CA 002434691 A CA002434691 A CA 002434691A CA 2434691 A CA2434691 A CA 2434691A CA 2434691 A1 CA2434691 A1 CA 2434691A1
- Authority
- CA
- Canada
- Prior art keywords
- propentofylline
- composition
- iop
- glaucoma
- additional agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 229960002934 propentofylline Drugs 0.000 title claims abstract description 56
- 230000004410 intraocular pressure Effects 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 25
- 208000010412 Glaucoma Diseases 0.000 claims description 15
- 206010030043 Ocular hypertension Diseases 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 9
- 210000003717 douglas' pouch Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 210000001585 trabecular meshwork Anatomy 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 12
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 6
- 102100030416 Stromelysin-1 Human genes 0.000 description 6
- 101710108790 Stromelysin-1 Proteins 0.000 description 6
- 229960001476 pentoxifylline Drugs 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 4
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 229940103988 Adenosine uptake inhibitor Drugs 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- HNFYOKRWFUQBIE-UHFFFAOYSA-N 7-(2-hydroxypropyl)-3-methyl-1-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CC(O)C HNFYOKRWFUQBIE-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001160 latanoprost Drugs 0.000 description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 201000006366 primary open angle glaucoma Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LBMAEBPZXXNKMZ-VIFPVBQESA-N (2s)-2-amino-n-hydroxy-3-(1h-indol-3-yl)propanamide Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NO)=CNC2=C1 LBMAEBPZXXNKMZ-VIFPVBQESA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GGUSQTSTQSHJAH-FQEVSTJZSA-N (R)-eliprodil Chemical compound C([C@H](O)C=1C=CC(Cl)=CC=1)N(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-FQEVSTJZSA-N 0.000 description 1
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 101000573882 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP3 Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- -1 Hydroxypropyl Chemical group 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000007950 Ocular Hypotension Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 208000014245 Ocular vascular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940087458 alcaine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 229950005455 eliprodil Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940095437 iopidine Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004771 levobetaxolol Drugs 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- 208000033672 open angle E glaucoma 1 Diseases 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 108010052605 prostromelysin Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 description 1
- 229960002341 trifluperidol Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 229960004317 unoprostone Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods for controlling intraocular pressure with propentofylline are disclosed.
Description
USE OF PROPENTOFYLLINE TO CONTROL
INTRAOCULAR PRESSURE
The present invention is directed to the use of propentofylline for controlling s intraocular pressure (IOP), particularly the elevated intraocular pressure _associated with glaucoma and/or ocular hypertension.
Background of the Invention io Glaucoma is an ocular disease associated with optic nerve head degeneration and loss of vision, which may lead to irreversible blindness. Elevated IOP
(ocular hypertension) is a major risk factor of glaucoma. IOP is regulated by the balance between the rate of aqueous humor production from the ciliary epithelium and the rate of its outflow through the trabecular meshwork (TM) and the uveal scleral pathway.
is In primary open angle glaucoma, the abnormal increase in IOP is mainly due to pathological changes in the TM leading to a significant reduction of outflow facility (Langham, The physiology and pathology of the intraocular pressure. In:
Bellows, ed.
Glaucoma: Contemporar y international concepts. New York: Masson Publishing, 1979:24-48; Segawa, Electron microscopic changes in the trabecular tissue in primary no open angle glaucoma. In: Bellows, ed. Glaucoma: Contemporary international concepts. New York: Masson Publishing, 1979:17-23; Rohen, Why is intraocular pressure elevated in chronic simple glaucoma? Anatomical consideration, Ophthalmology 1983;90:758-76S).
as It has been reported that the resistance of aqueous humor outflow through the TM is normally regulated in part by the ongoing extracellular matrix turnover in the TM (Bradley, et al., Effective matrix metalloproteinases activity on outflow in perfused human organ culture, Investigative Ophthalmology & Visual Science, 1998;39:2649-2658). Matrix metalloproteinases (MMPs) have been proposed as 3o important enzymes regulating the turnover of extracellular matrix in the TM
(Alexander, et al., Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork, Investigative Ophthalmology & Visual Science, 1991;32:172-180.1991; Acott, Trabecular extracellular matrix regulation. In: Drance, Van Buskirk, & Neufeld, eds. Pharmacology of Glaucoma. Baltimore: Williams & Wilkins, 3s 1992:125-127.1992; Samples, et al., Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone, Investigative Ophthalmology & Trisual Science, 1993;34:3386-3395). Activation of these enzymes could theoretically reduce the excessive and congestive extracellular I
matrix in the glaucomatous eye and in turn decrease fluid resistance of the outflow pathway. Indeed, when purified metalloproteinases (MMP-2, MMP-3 and MMP-9) were used to perfuse the human anterior segment, outflow facility increased by more than 50% lasting for at least 5 days (Bradley, et al., Effective matrix s metalloproteinases activity on outflow in perfused human organ culture, Investigative Ophthalmology & Visual Sciev~ce, 1998;39:2649-2658). Similarly, perfusion of the anterior segment with interleukin-la, a cytokine known to increase the expression of matrix metalloproteinases in the TM, also augmented the outflow facility (Bradley, et al., Effective matrix metalloproteinases activity on outflow in perfused human organ io culture, Investigative Ophthalmology 8~ Visual Science, 1998;39:2649-2658).
In contrast, metalloproteinase inhibitors, whether peptides (such as tissue inhibitor of metalloproteinase) or non-peptides (such as minocylcine, L-tryptophan hydroxamate), suppressed aqueous outflow. Furthermore, Acott, et al. (U.5. Patent No.
5,260,059) have disclosed a method for treating open-angle glaucoma with a substance to is modulate the ratio of matrix metalloproteinases (MMP) to tissue inhibitor of metalloproteinase (TIMP) or MMP/TIMP. The inventors' most preferred substances to achieve this include matrix metalloproteinases, see Column 3, lines 33-37.
Propentofylline (HWA 285; 3-methyl-1-(5'-oxohexyl)-7-propyl-xanthine) is a Zo peripheral vasodilator. It is disclosed in U.S. Patent No. 4,289,776 (Mohler, et al.) as useful for treating arterial blood flow disturbance or vascular dilatory insufficiency; in U.S. Patent 4,636,507 (Sheetz) for treating host defense mechanisms against trauma;
in U.S. Patent No. 5,310,666 (Aretz, et al.) for the treatment of peripheral, cerebral, and ocular vascular disorders; and in U.S. Patent No. 4,719,212 (Goto, et al.) for as treating cerebral disturbance; and in U.S. Patent No. 5,762,953 (Venkateshwaran) for treating Alzheimers disease; and in U.S. Patent No. 5,409,935 (Schubert, et al.) for treating secondary nerve cell damage and functional disorders after cranio-cerebral traumas; and in U.S. Patent No. 6,037,347 (Schubert, et al.) for treating dementia.
so In U.S. Patent No. 5,780,450 (Shade), adenosine uptake inhibitors are disclosed as being useful for treating retinal and optic nerve head damage following acute or chronic glaucoma, edema, ischemia, hypoxia, or trauma. The adenosine uptake inhibitors disclosed in the patent (including propentofylline) inhibit the uptake or re-absorption of adenosine into the neural cells of ocular tissues and thus help ss protect the neural cells from damage triggered by or resulting from the above-referenced conditions. The use of adenosine uptake inhibitors for lowering or controlling IOP is not disclosed or suggested. Propentofylline has also been determined to be a neurotrophic factor stimulator which could be useful to treat
INTRAOCULAR PRESSURE
The present invention is directed to the use of propentofylline for controlling s intraocular pressure (IOP), particularly the elevated intraocular pressure _associated with glaucoma and/or ocular hypertension.
Background of the Invention io Glaucoma is an ocular disease associated with optic nerve head degeneration and loss of vision, which may lead to irreversible blindness. Elevated IOP
(ocular hypertension) is a major risk factor of glaucoma. IOP is regulated by the balance between the rate of aqueous humor production from the ciliary epithelium and the rate of its outflow through the trabecular meshwork (TM) and the uveal scleral pathway.
is In primary open angle glaucoma, the abnormal increase in IOP is mainly due to pathological changes in the TM leading to a significant reduction of outflow facility (Langham, The physiology and pathology of the intraocular pressure. In:
Bellows, ed.
Glaucoma: Contemporar y international concepts. New York: Masson Publishing, 1979:24-48; Segawa, Electron microscopic changes in the trabecular tissue in primary no open angle glaucoma. In: Bellows, ed. Glaucoma: Contemporary international concepts. New York: Masson Publishing, 1979:17-23; Rohen, Why is intraocular pressure elevated in chronic simple glaucoma? Anatomical consideration, Ophthalmology 1983;90:758-76S).
as It has been reported that the resistance of aqueous humor outflow through the TM is normally regulated in part by the ongoing extracellular matrix turnover in the TM (Bradley, et al., Effective matrix metalloproteinases activity on outflow in perfused human organ culture, Investigative Ophthalmology & Visual Science, 1998;39:2649-2658). Matrix metalloproteinases (MMPs) have been proposed as 3o important enzymes regulating the turnover of extracellular matrix in the TM
(Alexander, et al., Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork, Investigative Ophthalmology & Visual Science, 1991;32:172-180.1991; Acott, Trabecular extracellular matrix regulation. In: Drance, Van Buskirk, & Neufeld, eds. Pharmacology of Glaucoma. Baltimore: Williams & Wilkins, 3s 1992:125-127.1992; Samples, et al., Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone, Investigative Ophthalmology & Trisual Science, 1993;34:3386-3395). Activation of these enzymes could theoretically reduce the excessive and congestive extracellular I
matrix in the glaucomatous eye and in turn decrease fluid resistance of the outflow pathway. Indeed, when purified metalloproteinases (MMP-2, MMP-3 and MMP-9) were used to perfuse the human anterior segment, outflow facility increased by more than 50% lasting for at least 5 days (Bradley, et al., Effective matrix s metalloproteinases activity on outflow in perfused human organ culture, Investigative Ophthalmology & Visual Sciev~ce, 1998;39:2649-2658). Similarly, perfusion of the anterior segment with interleukin-la, a cytokine known to increase the expression of matrix metalloproteinases in the TM, also augmented the outflow facility (Bradley, et al., Effective matrix metalloproteinases activity on outflow in perfused human organ io culture, Investigative Ophthalmology 8~ Visual Science, 1998;39:2649-2658).
In contrast, metalloproteinase inhibitors, whether peptides (such as tissue inhibitor of metalloproteinase) or non-peptides (such as minocylcine, L-tryptophan hydroxamate), suppressed aqueous outflow. Furthermore, Acott, et al. (U.5. Patent No.
5,260,059) have disclosed a method for treating open-angle glaucoma with a substance to is modulate the ratio of matrix metalloproteinases (MMP) to tissue inhibitor of metalloproteinase (TIMP) or MMP/TIMP. The inventors' most preferred substances to achieve this include matrix metalloproteinases, see Column 3, lines 33-37.
Propentofylline (HWA 285; 3-methyl-1-(5'-oxohexyl)-7-propyl-xanthine) is a Zo peripheral vasodilator. It is disclosed in U.S. Patent No. 4,289,776 (Mohler, et al.) as useful for treating arterial blood flow disturbance or vascular dilatory insufficiency; in U.S. Patent 4,636,507 (Sheetz) for treating host defense mechanisms against trauma;
in U.S. Patent No. 5,310,666 (Aretz, et al.) for the treatment of peripheral, cerebral, and ocular vascular disorders; and in U.S. Patent No. 4,719,212 (Goto, et al.) for as treating cerebral disturbance; and in U.S. Patent No. 5,762,953 (Venkateshwaran) for treating Alzheimers disease; and in U.S. Patent No. 5,409,935 (Schubert, et al.) for treating secondary nerve cell damage and functional disorders after cranio-cerebral traumas; and in U.S. Patent No. 6,037,347 (Schubert, et al.) for treating dementia.
so In U.S. Patent No. 5,780,450 (Shade), adenosine uptake inhibitors are disclosed as being useful for treating retinal and optic nerve head damage following acute or chronic glaucoma, edema, ischemia, hypoxia, or trauma. The adenosine uptake inhibitors disclosed in the patent (including propentofylline) inhibit the uptake or re-absorption of adenosine into the neural cells of ocular tissues and thus help ss protect the neural cells from damage triggered by or resulting from the above-referenced conditions. The use of adenosine uptake inhibitors for lowering or controlling IOP is not disclosed or suggested. Propentofylline has also been determined to be a neurotrophic factor stimulator which could be useful to treat
2 ophthalmic neurodegeneration resulting from various conditions, including glaucoma (W0/00/32197, Alcon Laboratories, Tnc.) None of the above publications disclose the use of propentofylline for s lowering or controlling IOP, or its effect on the regulation of MMP
expression in ocular tissues.
Pentoxifylline is a close analog of propentofylline. Topical instillation of 2°1°
pentoxifylline was reported to produce a slight decrease in IOP in ocular normotensive io rabbits (Hariton, Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterease inhibitors, Euf~opean Journal of Pharrrzacology, 1994;258:85-94).
This manuscript also describes the IOP-lowering effect of pentoxifylline when it was administered in combination with other compounds such as 3-(3-hydroxyphenyl)-N-n propylpiperidine, and trifluperidol. However, propentofylline was not studied or is mentioned in this report.
Summary of the Invention The present invention is directed to methods for controlling intraocular ao pressure in humans with propentofylline.
Description of the Preferred Embodiments Propentofylline was unexpectedly discovered to stimulate the expression of is metalloproteinase-3 (MMP-3; stromelysin) in cultured human trabecular meshwork cells. Incubation of the cells with 100 ~.M propentofylline for 72 hours significantly increased the expression of MMP-3 (Figure 1, upper panel). This unexpected effect was unique to propentofylline, since other adenosine reuptake inhibitors and close chemical analogs of propentofylline, such as dipyridamole, pentoxifylline, and so hydroxy-propentofylline, did not produce a statistically significant change in MMP-3 expression in the TM cells (Figure l, lower panel). This stimulatory effect unique to propentofylline on MMP-3 production by the TM cells suggests that it may modulate the aqueous hydrodynamics in the eye and affect IOP.
ss Despite the lack of prior evidence that propentofylline lowers IOP, we found that this compound unexpectedly increases the aqueous outflow facility in the human ocular perfusion organ culture. In this ex vivo study, the anterior segments of non-glaucomatous donor eyes were perfused continuously with 100 ~M of propentofylline.
On days 2 and 3 after the initiation of perfusion, the outflow rates of eyes receiving
expression in ocular tissues.
Pentoxifylline is a close analog of propentofylline. Topical instillation of 2°1°
pentoxifylline was reported to produce a slight decrease in IOP in ocular normotensive io rabbits (Hariton, Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterease inhibitors, Euf~opean Journal of Pharrrzacology, 1994;258:85-94).
This manuscript also describes the IOP-lowering effect of pentoxifylline when it was administered in combination with other compounds such as 3-(3-hydroxyphenyl)-N-n propylpiperidine, and trifluperidol. However, propentofylline was not studied or is mentioned in this report.
Summary of the Invention The present invention is directed to methods for controlling intraocular ao pressure in humans with propentofylline.
Description of the Preferred Embodiments Propentofylline was unexpectedly discovered to stimulate the expression of is metalloproteinase-3 (MMP-3; stromelysin) in cultured human trabecular meshwork cells. Incubation of the cells with 100 ~.M propentofylline for 72 hours significantly increased the expression of MMP-3 (Figure 1, upper panel). This unexpected effect was unique to propentofylline, since other adenosine reuptake inhibitors and close chemical analogs of propentofylline, such as dipyridamole, pentoxifylline, and so hydroxy-propentofylline, did not produce a statistically significant change in MMP-3 expression in the TM cells (Figure l, lower panel). This stimulatory effect unique to propentofylline on MMP-3 production by the TM cells suggests that it may modulate the aqueous hydrodynamics in the eye and affect IOP.
ss Despite the lack of prior evidence that propentofylline lowers IOP, we found that this compound unexpectedly increases the aqueous outflow facility in the human ocular perfusion organ culture. In this ex vivo study, the anterior segments of non-glaucomatous donor eyes were perfused continuously with 100 ~M of propentofylline.
On days 2 and 3 after the initiation of perfusion, the outflow rates of eyes receiving
3 propentofylline were significantly increased when compared to vehicle-treated eyes (Example 2).
When propentofylline was tested in the rabbit for its potential effect on IOP.
It s did not produce a statistically significant change (Table 1 ). In this study, the rabbits were placed in restrainers, and IOP was determined with an Alcon Pneumatonometer after light corneal anesthesia with 0.1 % proparacaine (Alcaine~ diluted with physiological saline). Following each IOP measurement, residual anesthetic was washed away with saline. After two baseline measurements, animals were dosed io topically on the cornea with vehicle or propentofylline (2 x 25 ~.L, 1%
solution). IOP
measurements were then taken at indicated intervals. This finding indicates that topical administration of 500 ~g propentofylline onto the eye did not affect the IOP of rabbits. The compound was well tolerated in this study.
is Table 1. Lack of effect of Propentofylline (500 pg) in Rabbit IOP
Time after IOP % Change (mmH in ) IOP
Treatment (hour)Mean SEM Mean SEM
0 23.5 0.9 0.0 0.0 1 21.0 0.7 -10.0 3.0 3 23.6 0.9 1.3 4.7 23.5 0.3 1.1 3.4 7 24.0 0.5 4.7 6.2 l~lote: n= 1U. No statistical significance observed.
When propentofylline was tested in the rabbit for its potential effect on IOP.
It s did not produce a statistically significant change (Table 1 ). In this study, the rabbits were placed in restrainers, and IOP was determined with an Alcon Pneumatonometer after light corneal anesthesia with 0.1 % proparacaine (Alcaine~ diluted with physiological saline). Following each IOP measurement, residual anesthetic was washed away with saline. After two baseline measurements, animals were dosed io topically on the cornea with vehicle or propentofylline (2 x 25 ~.L, 1%
solution). IOP
measurements were then taken at indicated intervals. This finding indicates that topical administration of 500 ~g propentofylline onto the eye did not affect the IOP of rabbits. The compound was well tolerated in this study.
is Table 1. Lack of effect of Propentofylline (500 pg) in Rabbit IOP
Time after IOP % Change (mmH in ) IOP
Treatment (hour)Mean SEM Mean SEM
0 23.5 0.9 0.0 0.0 1 21.0 0.7 -10.0 3.0 3 23.6 0.9 1.3 4.7 23.5 0.3 1.1 3.4 7 24.0 0.5 4.7 6.2 l~lote: n= 1U. No statistical significance observed.
4 In the same study, it was also found that similar to propentofylline, pentoxifylline did not significantly lower IOP in the rabbit (Table 2).
s Table 2. Lack of effect of Pentoxifylline (500 p.g) in Rabbit IOP
Time after IOP % Chan mmH a in ) IOP
Treatment (hour)Mean SEM Mean SEM
0 23.8 0.8 0.0 0.0 1 2I.6 I.0 -8.9 2.8 3 23.1 0.4 -1.8 3.8 27.8 0.6 17.5 3.6 7 27.3 0.6 15.9 5.2 l~lote: n = 1 U. No statistical significance observed.
IOP responses in the rabbit eye to various pharmacological agents do not io always correspond to IOP responses in primates. For example, clinically active IOP-lowering compounds, such as latanoprost or pilocarpine, had no measurable effect on TOP in the rabbit (Dinslage, et al., Intraocular pressure in rabbits by telemetry II:
effects of animal handling and drugs, Irwestigative Ophthalmology & Visual .Science, 1998;39:2485-2489; Van Bijsterveld, et al., The effect of hypotensive drugs on the is intraocular pressure after waterloading in rabbits, Documenta Ophthalmologica, 1981;52:189-198). Hence, experimental data regarding IOP obtained from the rabbit cannot be generalized to predict pharmacological actions in primates, including humans.
ao The IOP-lowering effect of propentofylline in primates was discovered when tested in ocular hypertensive monkeys. In this animal model, the IOP of cynomolgus monkeys was artificially elevated by laser-induced photocoagulation of the TM.
When 500 ~g of propentofylline in aqueous solution was instilled onto the surface of the lasered eye of unanesthetized monkeys, it caused a dramatic decrease in IOP
as (Figure 3, upper panel). This IOP-lowering effect persisted even after 7 consecutive days of drug treatment (500 fig, twice daily) (Figure 3, lower panel). As with rabbits, the compound was well tolerated.
The compositions of the present invention comprise propentofylline and a so pharmaceutically acceptable vehicle. As used herein, the term "pharmaceutically acceptable vehicle" refers to any formulation that is acceptable, i.e., is safe and provides the appropriate delivery of an effective amount of propentofylline for the desired route of administration. The compositions of the present invention may be
s Table 2. Lack of effect of Pentoxifylline (500 p.g) in Rabbit IOP
Time after IOP % Chan mmH a in ) IOP
Treatment (hour)Mean SEM Mean SEM
0 23.8 0.8 0.0 0.0 1 2I.6 I.0 -8.9 2.8 3 23.1 0.4 -1.8 3.8 27.8 0.6 17.5 3.6 7 27.3 0.6 15.9 5.2 l~lote: n = 1 U. No statistical significance observed.
IOP responses in the rabbit eye to various pharmacological agents do not io always correspond to IOP responses in primates. For example, clinically active IOP-lowering compounds, such as latanoprost or pilocarpine, had no measurable effect on TOP in the rabbit (Dinslage, et al., Intraocular pressure in rabbits by telemetry II:
effects of animal handling and drugs, Irwestigative Ophthalmology & Visual .Science, 1998;39:2485-2489; Van Bijsterveld, et al., The effect of hypotensive drugs on the is intraocular pressure after waterloading in rabbits, Documenta Ophthalmologica, 1981;52:189-198). Hence, experimental data regarding IOP obtained from the rabbit cannot be generalized to predict pharmacological actions in primates, including humans.
ao The IOP-lowering effect of propentofylline in primates was discovered when tested in ocular hypertensive monkeys. In this animal model, the IOP of cynomolgus monkeys was artificially elevated by laser-induced photocoagulation of the TM.
When 500 ~g of propentofylline in aqueous solution was instilled onto the surface of the lasered eye of unanesthetized monkeys, it caused a dramatic decrease in IOP
as (Figure 3, upper panel). This IOP-lowering effect persisted even after 7 consecutive days of drug treatment (500 fig, twice daily) (Figure 3, lower panel). As with rabbits, the compound was well tolerated.
The compositions of the present invention comprise propentofylline and a so pharmaceutically acceptable vehicle. As used herein, the term "pharmaceutically acceptable vehicle" refers to any formulation that is acceptable, i.e., is safe and provides the appropriate delivery of an effective amount of propentofylline for the desired route of administration. The compositions of the present invention may be
5 administered orally, or they may be administered locally to the eye via topical dosing or by a continuous release device placed in the cul-de-sac of the eye.
Propentofylline can be incorporated into a formulation, such as a tablet or a s capsule, for oral administration. Hence, 100-1000 mg of propentofylline may be combined with inactive ingredients such as starch, lactose and magnesium stearate and formulated according to procedures known to those skilled in the art of tablet or capsule formulation. An example of a tablet formulation is shown in Example 4.
This formulation will be administered to patients 1 to 6 times daily, 1 to 3 tablets each io time.
Propentofylline can be incorporated into various types of ophthalmic formulations for delivery to the eye. The compound may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, is penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution. Ophthalmic solution formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound. Furthermore, the ao ophthalmic solution may contain a thickener such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctiva) sac. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, is mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.
Propentofylline can also be incorporated in a continuous release system that will be placed in the cui-de-sac of the eye. Examples of such devices are shown by Zattaroni (U.S. Patent No. 4,186,184). The release rate of propentofylline in this device will be 10 ~,g/hour to 1 mg/hour.
Propentofylline is preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4.5 to 8Ø It will normally be contained in these formulations in an amount 0.1 % to 5% by weight, but preferably in an amount of
Propentofylline can be incorporated into a formulation, such as a tablet or a s capsule, for oral administration. Hence, 100-1000 mg of propentofylline may be combined with inactive ingredients such as starch, lactose and magnesium stearate and formulated according to procedures known to those skilled in the art of tablet or capsule formulation. An example of a tablet formulation is shown in Example 4.
This formulation will be administered to patients 1 to 6 times daily, 1 to 3 tablets each io time.
Propentofylline can be incorporated into various types of ophthalmic formulations for delivery to the eye. The compound may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, is penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution. Ophthalmic solution formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound. Furthermore, the ao ophthalmic solution may contain a thickener such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctiva) sac. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, is mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.
Propentofylline can also be incorporated in a continuous release system that will be placed in the cui-de-sac of the eye. Examples of such devices are shown by Zattaroni (U.S. Patent No. 4,186,184). The release rate of propentofylline in this device will be 10 ~,g/hour to 1 mg/hour.
Propentofylline is preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4.5 to 8Ø It will normally be contained in these formulations in an amount 0.1 % to 5% by weight, but preferably in an amount of
6 0.2% to 3% by weight. An example of a topical ophthalmic formulation is presented in Example 5. Thus, for topical presentation 1 to 3 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the routine discretion of a skilled clinician.
s Propentofylline can also be used in combination with other agents for treating glaucoma, such as, but not limited to, /3-blockers (e.g., timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol), carbonic anhydrase inhibitors (e.g., brinzolamide and dorzolamide), al antagonists (e.g. nipradolol), a2 agonists io (e.g., iopidine and brimonidine), miotics (e.g., pilocarpine and epinephrine), prostaglandin analogues (e.g., latanoprost, travaprost, unoprostone, bimatoprost, and compounds set forth in U.S. Patent Nos. 5,889,052; 5,296,504; 5,422,368;
5,688,819;
and 5,151,444, "hypotensive lipids" (e.g., compounds set forth in 5,352,708), serotonergics, and neuroprotectants (e.g., compounds from U.S. Patent No.
4,690,931, is particularly eliprodil and R-eliprodil, as set forth in a pending application U.S.S.N.
06/203350, and appropriate compounds from W094/13275, such as, memantine.
ao Effect of Various Compounds on MMP-3 Expression in Cultured Human Trabecular Meshwork (HTM-35D) Cells Human TM cells were isolated, characterized and cultured as described (Steely et al, The effects of dexamethasone on fibronectin expression in cultured human is trabecular meshwork cells, Investigative Ophthalmology and Visual Science, 1992;33:2242-2250) They were maintained at 5% C02 and 37°C in a medium consisting of Dulbecco's modif ed Eagle medium with Glutamax I supplemented with 10% fetal bovine serum and SO~g/mL gentamicin. Confluent cell cultures were treated with the indicated compounds at the indicated final concentration for 72 hours so and the medium assayed for proMMP-3 by a commercially available ELISA assay kit.
(See Figure l.) Abbreviations: PPF-OH is hydroxypropentofylline.
3s Effect of Propentofylline on Outflow in Human Ocular Perfusion Organ Culture Human ocular perfusion organ culture was performed as described (Tschumper, et al. Glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Current Eye Research, 1990;9:363-369; Clark et al, Dexamethasone-
s Propentofylline can also be used in combination with other agents for treating glaucoma, such as, but not limited to, /3-blockers (e.g., timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol), carbonic anhydrase inhibitors (e.g., brinzolamide and dorzolamide), al antagonists (e.g. nipradolol), a2 agonists io (e.g., iopidine and brimonidine), miotics (e.g., pilocarpine and epinephrine), prostaglandin analogues (e.g., latanoprost, travaprost, unoprostone, bimatoprost, and compounds set forth in U.S. Patent Nos. 5,889,052; 5,296,504; 5,422,368;
5,688,819;
and 5,151,444, "hypotensive lipids" (e.g., compounds set forth in 5,352,708), serotonergics, and neuroprotectants (e.g., compounds from U.S. Patent No.
4,690,931, is particularly eliprodil and R-eliprodil, as set forth in a pending application U.S.S.N.
06/203350, and appropriate compounds from W094/13275, such as, memantine.
ao Effect of Various Compounds on MMP-3 Expression in Cultured Human Trabecular Meshwork (HTM-35D) Cells Human TM cells were isolated, characterized and cultured as described (Steely et al, The effects of dexamethasone on fibronectin expression in cultured human is trabecular meshwork cells, Investigative Ophthalmology and Visual Science, 1992;33:2242-2250) They were maintained at 5% C02 and 37°C in a medium consisting of Dulbecco's modif ed Eagle medium with Glutamax I supplemented with 10% fetal bovine serum and SO~g/mL gentamicin. Confluent cell cultures were treated with the indicated compounds at the indicated final concentration for 72 hours so and the medium assayed for proMMP-3 by a commercially available ELISA assay kit.
(See Figure l.) Abbreviations: PPF-OH is hydroxypropentofylline.
3s Effect of Propentofylline on Outflow in Human Ocular Perfusion Organ Culture Human ocular perfusion organ culture was performed as described (Tschumper, et al. Glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Current Eye Research, 1990;9:363-369; Clark et al, Dexamethasone-
7 induced ocular hypertension in perfusion-cultured human eyes. Investigative Ophthalmology and Visual Science 1995;36:478-489). Briefly, human cadaver eyes, 16 to 20 hours post mortem, were dissected at the equator and the lens, vitreous and iris were removed. The anterior segment of the eye, including cornea s and sclera ring containing TM and ciliary body, was placed into a custom-made plexiglass culture dish and sealed in place with a plexiglass O-ring. Culture media (Dulbecco's modified Eagle medium) was placed in a reservoir and perfused through a central cannula in the bottom of the dish. The reservoir was raised to generate approximately 11 xnrnHg of hydrostatic pressure relative to the center of io the perfused eye. The weight of the reservoir was recorded daily. Outflow rate was defined as the change in the weight of the reservoir per unit time.
After a 2-4 days stabilization period, the eyes were perfused with either 100 ~.M propentofylline (PPF) or vehicle alone and their outflow rates monitored for is another 4 days. * represents p<0.05 by Student's t-test. (See Figure 2.) Zo IOP-Lowering Effect of Propentofylline in Lasered Monkey Eyes Top Panel: IOP-lowering effect of Propentofylline (PPF) (500 fig) in lasered monkey eyes. It clearly reduced IOP at 1 hour after topical ocular dosing.
as Bottom Panel: Propentofylline was ocular hypotensive even after repeated doses. These monkeys received 500 pg of propentofylline twice daily for the indicated days and the IOP was measured right after the morning dosing. IOP of the eyes receiving vehicle control did not change (data not shown).
so Studies were performed as described previously (Toris, et al., Aqueous humor dynamics in monkeys with laser-induced glaucoma, Journal of Ocular Pharmacology a~cd Therapeutics, 2000;16:19-27). (See Figure 3.)
After a 2-4 days stabilization period, the eyes were perfused with either 100 ~.M propentofylline (PPF) or vehicle alone and their outflow rates monitored for is another 4 days. * represents p<0.05 by Student's t-test. (See Figure 2.) Zo IOP-Lowering Effect of Propentofylline in Lasered Monkey Eyes Top Panel: IOP-lowering effect of Propentofylline (PPF) (500 fig) in lasered monkey eyes. It clearly reduced IOP at 1 hour after topical ocular dosing.
as Bottom Panel: Propentofylline was ocular hypotensive even after repeated doses. These monkeys received 500 pg of propentofylline twice daily for the indicated days and the IOP was measured right after the morning dosing. IOP of the eyes receiving vehicle control did not change (data not shown).
so Studies were performed as described previously (Toris, et al., Aqueous humor dynamics in monkeys with laser-induced glaucoma, Journal of Ocular Pharmacology a~cd Therapeutics, 2000;16:19-27). (See Figure 3.)
8 A tablet formulation suitable for oral administration, and useful for controlling intraocular pressure.
Ingredient Amount per Tablet (mg) Propentofylline 300 Cornstarch SO
Lactose 14S
Magnesium stearate S
A topical ophthalmic composition useful for treating ocular hypertension:
Ingredient Concentration (% w/v) Propentofylline 1 Dibasic Sodium Phosphate0.2 Hydroxypropyl methylcellulose0.5 Polysorbate 80 0.05 Benzalkonium Chloride 0.01 Sodium Chloride 0.7 Edetate Disodium 0.01 NaOH/HCl q.s., pH 7.4 Purified Water q.s. 100%
Ingredient Amount per Tablet (mg) Propentofylline 300 Cornstarch SO
Lactose 14S
Magnesium stearate S
A topical ophthalmic composition useful for treating ocular hypertension:
Ingredient Concentration (% w/v) Propentofylline 1 Dibasic Sodium Phosphate0.2 Hydroxypropyl methylcellulose0.5 Polysorbate 80 0.05 Benzalkonium Chloride 0.01 Sodium Chloride 0.7 Edetate Disodium 0.01 NaOH/HCl q.s., pH 7.4 Purified Water q.s. 100%
Claims (17)
1. A method for controlling intraocular pressure associated with glaucoma or ocular hypertension, which comprises administering a pharmaceutically effective dose of propentofylline.
2 The method of claim 1 which additionally comprises administering an additional agent which is for treating glaucoma or ocular hypertension.
3 The method of claim 1 wherein the propentofylline is administered orally.
4 The method of claim 3 wherein 100-1000 mg of propentofylline is orally administered.
The method of claim 1 wherein the propentofylline is administered topically to an eye.
6 The method of claim 5 wherein the propentofylline is delivered in a topical formulation at a concentration of 0.1-5 percent by weight.
7 The method of claim 1 wherein the propentofylline is delivered in a continuous release system placed in the cul-de-sac of an eye.
8 Use of propentofylline for the preparation of a pharmaceutical composition for controlling intraocular pressure associated with glaucoma or ocular hypertension.
9 The use according to claim 8 with an additional agent which is for treating glaucoma or ocular hypertension for the preparation of a pharmaceutical composition for treating glaucoma or ocular hypertension.
The use of claim 8 wherein the composition is an oral composition.
11 The use of claim 8 wherein the composition is a topical ophthalmic composition.
12. The use of Claim 11 wherein the propentofylline concentration is 0.1-5 percent by weight.
13. The use of Claim 8 wherein the composition is a continuous release composition placed in the cul-de-sac of an eye.
14. The method of Claim 2 wherein the propentofylline and the additional agent are dosed in separate compositions.
15. The method of Claim 2 wherein the propentofylIine and the additional agent are dosed in a common composition.
16. The use of Claim 9 wherein the additional agent is in a separate composition from propentofylline.
17. The use of Claim 9 wherein the additional agent is in a common composition with propentofylline.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27754801P | 2001-03-21 | 2001-03-21 | |
US60/277,548 | 2001-03-21 | ||
PCT/US2002/005456 WO2002076460A2 (en) | 2001-03-21 | 2002-02-22 | Use of propentofylline to control intraocular pressure |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2434691A1 true CA2434691A1 (en) | 2002-10-03 |
Family
ID=23061335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002434691A Abandoned CA2434691A1 (en) | 2001-03-21 | 2002-02-22 | Use of propentofylline to control intraocular pressure |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1370267A2 (en) |
JP (1) | JP2004528310A (en) |
AR (1) | AR032812A1 (en) |
BR (1) | BR0208146A (en) |
CA (1) | CA2434691A1 (en) |
MX (1) | MXPA03008491A (en) |
WO (1) | WO2002076460A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010016043A1 (en) * | 2008-08-05 | 2010-02-11 | University College Cork, National University Of Ireland, Cork | Treatment of retinal degeneration |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
-
2002
- 2002-02-20 AR ARP020100581A patent/AR032812A1/en not_active Application Discontinuation
- 2002-02-22 BR BR0208146-6A patent/BR0208146A/en not_active IP Right Cessation
- 2002-02-22 CA CA002434691A patent/CA2434691A1/en not_active Abandoned
- 2002-02-22 JP JP2002574975A patent/JP2004528310A/en active Pending
- 2002-02-22 MX MXPA03008491A patent/MXPA03008491A/en unknown
- 2002-02-22 WO PCT/US2002/005456 patent/WO2002076460A2/en not_active Application Discontinuation
- 2002-02-22 EP EP02719062A patent/EP1370267A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AR032812A1 (en) | 2003-11-26 |
WO2002076460A2 (en) | 2002-10-03 |
JP2004528310A (en) | 2004-09-16 |
MXPA03008491A (en) | 2003-12-08 |
WO2002076460A3 (en) | 2003-04-03 |
EP1370267A2 (en) | 2003-12-17 |
BR0208146A (en) | 2004-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2496797C (en) | Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin | |
RU2297243C2 (en) | Inhibitors of glycogen synthase kinase-3 (gsk-3) in glaucoma treatment | |
JP4934653B2 (en) | Glaucoma treatment agent comprising Rho kinase inhibitor and β-blocker | |
US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
EP1740164B1 (en) | Statins for the treatment of ocular hypertension and glaucoma | |
KR20080016556A (en) | Prophylactic or therapeutic agent for corneal and conjunctival disorder | |
EP1752456B1 (en) | Corneal perception recovery drug containing amide compound | |
JP4482726B2 (en) | Glaucoma treatment agent comprising Rho kinase inhibitor and prostaglandins | |
RU2324483C2 (en) | Inhibitors of hystone deacetylase for treatment of degenerative eye diseases | |
KR100499903B1 (en) | 5ht2 agonists for controlling iop and treating glaucoma | |
AU2001216071A1 (en) | 5HT2 agonists for controlling IOP and treating glaucoma | |
CA2434691A1 (en) | Use of propentofylline to control intraocular pressure | |
US20040110776A1 (en) | Use of propentofylline to control intraocular pressure | |
US7867999B1 (en) | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions | |
AU2002250168A1 (en) | Use of propentofylline to control intraocular pressure | |
US6927233B1 (en) | 5ht2 agonists for controlling IOP and treating glaucoma | |
WO2006098292A1 (en) | Therapeutic agent for ophthalmic disease | |
US20070232675A1 (en) | Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma | |
KR20050013238A (en) | Remedy or preventive for keratoconjunctival epithelial cell injury | |
RENGARAJ VENKATESH | COMMONLY PRESCRIBED GLAUCOMA EYE DROPS AND ORAL MEDICATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |